Skip to main content

Ani Pharmaceuticals Inc

ANIP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001023024

In the last 90 days, Ani Pharmaceuticals Inc insiders filed 0 open-market purchases and 11 sales; 290 institutions reported holding it in 13F filings for Q3 2026, worth $1.66B in total; no superinvestor holds it.

Key figures

Market capNo recent share count in SEC filings
–
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $2.36M in total
11
13F holdersQ3 2026, −11 vs. previous quarter
290
13F valueReported value at the end of Q3 2026
$1.66B
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$883.4M
+43.8% year over year
Net income, FY2025
$78.3M
No comparable prior period
Free cash flow, FY2025
$171.4M
+258.7% year over year
Revenue, Q3 FY2026
$290.8M
+27.6% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
3.58M
Shares sold short
Change
+111.6K
+3.2% vs. previous
Days to cover
11.88
At average daily volume

Superinvestors holding ANIP, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding ANIP at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Ani Pharmaceuticals Inc insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 18, 2026 (view filing)8:32 PM ETNov 16-182 daysLalwani NikhilPRESIDENT & CEOSSale−5.40K$71.22−$384.6K−1.6%328.3K after2 lots10b5-1
Nov 13, 2026 (view filing)4:35 PM ETNov 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$70.80−$35.4K−0.7%72.9K after10b5-1
Oct 30, 2026 (view filing)4:36 PM ETOct 291 dayCarey Stephen P.SVP & CFOSSale−2.85K$72.87−$207.7K−1.7%166.1K after10b5-1
Oct 16, 2026 (view filing)6:50 PM ETOct 151 dayLalwani NikhilPRESIDENT & CEOSSale−5.40K$71.89−$388.2K−1.6%333.7K after10b5-1
Oct 13, 2026 (view filing)8:47 PM ETOct 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$73.59−$36.8K−0.7%73.4K after10b5-1
Sep 30, 2026 (view filing)4:52 PM ETSep 291 dayCarey Stephen P.SVP & CFOSSale−2.85K$73.00−$208.1K−1.7%169.0K after10b5-1
Sep 16, 2026 (view filing)4:20 PM ETSep 151 dayLalwani NikhilPRESIDENT & CEOSSale−5.40K$71.00−$383.4K−1.6%339.1K after10b5-1
Sep 14, 2026 (view filing)8:57 PM ETSep 113 daysThoma JeanneDirectorSSale−1.00K$71.53−$71.5K−3.6%26.8K after10b5-1
Sep 14, 2026 (view filing)8:56 PM ETSep 14Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$70.79−$35.4K−0.7%73.9K after10b5-1
Sep 1, 2026 (view filing)6:18 PM ETAug 311 dayCarey Stephen P.SVP & CFOSSale−2.85K$72.80−$207.5K−1.6%171.8K after10b5-1

Top 10 13F holders, Q3 2026

See all 290 holders

The largest institutional positions in Ani Pharmaceuticals Inc at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding ANIP in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.3,155,865$229.3M0.00%+197,219+6.7%Added
Soleus Capital Management, L.P.975,500$70.9M2.52%+107,740+12.4%Added
State Street Corp950,970$69.1M0.00%+119,323+14.3%Added
American Century Companies Inc912,647$66.3M0.03%+338,173+58.9%Added
Vanguard Capital Management LLC904,707$65.7M0.00%+66,483+7.9%Added
Dimensional Fund Advisors LP728,748$52.9M0.01%+105,285+16.9%Added
Tang Capital Management LLC707,500$51.4M2.36%00.0%Unchanged
UBS Group AG621,335$45.1M0.01%+323,796+108.8%Added
Geode Capital Management, LLC545,063$39.6M0.00%+8,656+1.6%Added
Deep Track Capital, LP500,000$36.3M0.61%+500,000New

Holders of 5% or more of ANIP

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Ani Pharmaceuticals Inc.

Largest holders of ANIP from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A12.80%2.90M shares+1.50 ppfrom 11.30%Oct 17, 20252 filingsJul 27, 2026SEC